Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Future Trends in Radioisotope-Based Imaging 2.0
share announcement

Future Trends in Radioisotope-Based Imaging 2.0

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 5457

Special Issue Editors

Dr. Rebecca Dumont

E-Mail
Guest Editor
Medical Faculty, University of Geneva, Geneva, Switzerland
Interests: the development of novel radiotracers and their clinical translation
Special Issues, Collections and Topics in MDPI journals
Dr. Pablo Jane

E-Mail
Guest Editor
Medical Faculty, University of Geneva, Geneva, Switzerland
Interests: the development of new approaches for image data processing and their clinical translation
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Martin Alexander Walter

E-Mail Website
Guest Editor
Medical Faculty, University of Geneva, Geneva, Switzerland
Interests: integrated diagnostics and its clinical implementation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Radioisotope-based imaging is a rapidly growing field that thrives on the constant development of new methods to detect, characterize, and better understand diseases. The recent past has witnessed a surge of new technological advancements that have touched every aspect of the field, such as the development, validation, and clinical implementation of new radiopharmaceuticals, automated radiopharmaceutical systems, new hybrid scanner technology, and novel approaches to process and analyze imaging data.

These developments, in addition to others, have broadened the role of radioisotope imaging in modern patient care by creating new diagnostic platforms in numerous clinical fields, including cardiology, neurology, and oncology. As such, radioisotope-based imaging is increasingly supporting clinical decision-making, monitoring the response to therapies, and ultimately improving therapeutic outcomes.

This Special Issue highlights the current developments, and we invite submissions of original research and comprehensive reviews on new radiopharmaceuticals, next-generation scanner technology, novel approaches on image data processing, and any area of research that will shape future trends in radioisotope-based imaging.

Dr. Rebecca Dumont
Dr. Pablo Jane
Prof. Dr. Martin Alexander Walter
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • positron emission tomography (PET)
  • PET radiomics
  • hybrid imaging
  • radiopharmaceuticals

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

10 pages, 1601 KiB  
Article
The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity
by Ayman Abouzayed, Jesper Borin, Fanny Lundmark, Anastasiya Rybina, Sophia Hober, Roman Zelchan, Vladimir Tolmachev, Vladimir Chernov and Anna Orlova
Diagnostics 2023, 13(9), 1611; https://doi.org/10.3390/diagnostics13091611 - 02 May 2023
Cited by 2 | Viewed by 1374
Abstract
Gastrin-releasing peptide receptors (GRPRs) are overexpressed in the majority of primary prostate tumors and in prostatic lymph node and bone metastases. Several GRPR antagonists were developed for SPECT and PET imaging of prostate cancer. We previously reported a preclinical evaluation of the GRPR [...] Read more.
Gastrin-releasing peptide receptors (GRPRs) are overexpressed in the majority of primary prostate tumors and in prostatic lymph node and bone metastases. Several GRPR antagonists were developed for SPECT and PET imaging of prostate cancer. We previously reported a preclinical evaluation of the GRPR antagonist [99mTc]Tc-maSSS-PEG2-RM26 (based on [D-Phe6, Sta13, Leu14-NH2]BBN(6-14)) which bound to GRPR with high affinity and had a favorable biodistribution profile in tumor-bearing animal models. In this study, we aimed to prepare and test kits for prospective use in an early-phase clinical study. The kits were prepared to allow for a one-pot single-step radiolabeling with technetium-99m pertechnetate. The kit vials were tested for sterility and labeling efficacy. The radiolabeled by using the kit GRPR antagonist was evaluated in vitro for binding specificity to GRPR on PC-3 cells (GRPR-positive). In vivo, the toxicity of the kit constituents was evaluated in rats. The labeling efficacy of the kits stored at 4 °C was monitored for 18 months. The biological properties of [99mTc]Tc-maSSS-PEG2-RM26, which were obtained after this period, were examined both in vitro and in vivo. The one-pot (gluconic acid, ethylenediaminetetraacetic acid, stannous chloride, and maSSS-PEG2-RM26) single-step radiolabeling with technetium-99m was successful with high radiochemical yields (>97%) and high molar activities (16–24 MBq/nmol). The radiolabeled peptide maintained its binding properties to GRPR. The kit constituents were sterile and non-toxic when tested in living subjects. In conclusion, the prepared kit is considered safe in animal models and can be further evaluated for use in clinics. Full article
(This article belongs to the Special Issue Future Trends in Radioisotope-Based Imaging 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

12 pages, 620 KiB  
Review
Molecular Imaging Diagnosis of Renal Cancer Using 99mTc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques
by Octavian Sabin Tataru, Michele Marchioni, Felice Crocetto, Biagio Barone, Giuseppe Lucarelli, Francesco Del Giudice, Gian Maria Busetto, Alessandro Veccia, Arturo Lo Giudice, Giorgio Ivan Russo, Stefano Luzzago, Mattia Luca Piccinelli, Mihai Dorin Vartolomei, Gennaro Musi and Matteo Ferro
Diagnostics 2023, 13(4), 593; https://doi.org/10.3390/diagnostics13040593 - 06 Feb 2023
Cited by 7 | Viewed by 2172
Abstract
Novel molecular imaging opportunities to preoperatively diagnose renal cell carcinoma is under development and will add more value in limiting the postoperative renal function loss and morbidity. We aimed to comprehensively review the research on single photon emission computed tomography/computed tomography (SPECT/CT) and [...] Read more.
Novel molecular imaging opportunities to preoperatively diagnose renal cell carcinoma is under development and will add more value in limiting the postoperative renal function loss and morbidity. We aimed to comprehensively review the research on single photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography computed tomography (PET-CT) molecular imaging and to enhance the urologists’ and radiologists’ knowledge of the current research pattern. We identified an increase in prospective and also retrospective studies that researched to distinguish between benign and malignant lesions and between different clear cell renal cell carcinoma subtypes, with small numbers of patients studied, nonetheless with excellent results on specificity, sensitivity and accuracy, especially for 99mTc-sestamibi SPECT/CT that delivers quick results compared to a long acquisition time for girentuximab PET-CT, which instead gives better image quality. Nuclear medicine has helped clinicians in evaluating primary and secondary lesions, and has lately returned with new and exciting insights with novel radiotracers to reinforce its diagnostic potential in renal carcinoma. To further limit the renal function loss and post-surgery morbidity, future research is mandatory to validate the results and to clinically implement the diagnostic techniques in the context of precision medicine. Full article
(This article belongs to the Special Issue Future Trends in Radioisotope-Based Imaging 2.0)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

4 pages, 1469 KiB  
Interesting Images
Histologically Confirmed Testicular Metastasis Revealed by [89Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging
by Florian Rosar, Caroline Burgard, Johannes Linxweiler, Mathias Wagner and Samer Ezziddin
Diagnostics 2023, 13(7), 1352; https://doi.org/10.3390/diagnostics13071352 - 05 Apr 2023
Cited by 1 | Viewed by 1254
Abstract
We present an interesting image of a testicular metastasis from prostate cancer revealed by [89Zr]Zr-PSMA-617 PET/CT imaging in a 70-year-old man with biochemical recurrence and negative conventional [68Ga]Ga-PSMA-11 PET/CT imaging. This case should encourage the consideration of [89 [...] Read more.
We present an interesting image of a testicular metastasis from prostate cancer revealed by [89Zr]Zr-PSMA-617 PET/CT imaging in a 70-year-old man with biochemical recurrence and negative conventional [68Ga]Ga-PSMA-11 PET/CT imaging. This case should encourage the consideration of [89Zr]Zr-PSMA-617 PET/CT if conventional PSMA PET/CT imaging had failed to localize biochemical recurrence, and may remind colleagues of this rare but potential metastatic localization in this setting. Full article
(This article belongs to the Special Issue Future Trends in Radioisotope-Based Imaging 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop